We are pleased to share that HIVPA is now part of BHIVA as the BHIVA Pharmacy Special Interest Group (SIG). This marks an exciting new chapter, strengthening collaboration and supporting the continued development of pharmacy practice within HIV care.
The BHIVA HIV Pharmacy Special Interest Group is looking for new committee members to join our team. We are currently recruiting for two key roles: Bulletin Co-Leads Education Co-Lead If you are interested please get in touch.
The University of Liverpool Drug Interactions Group presents The Liverpool Course: COVID-19. Join us on Zoom webinar on Wednesday 3rd December 2025 at 3PM GMT.
We are aware of our website issue - we are working on the getting it back on! 🙏🏻
Thank you everyone who attended our session and thanks our speakers Prof Alan Winston, Dilan Kartal and Yemi Daramola!
Recap from HIVPA session yesterday - first up: fostemsavir
Updates on CARES at CROI25, still comparable CVF rates with 2 or more risk factors @bhiva.bsky.social #BHIVA25
Promising data on DoxyPEP on reducing syphillis and chlamydia but not gonorrhoea due to high tetracycline resistance in Europe #BHIVA25 @bhiva.bsky.social
Have you thought about incorporating spirituality and religious practice conversations in your consultations? A few tips here.. @bhiva.bsky.social #BHIVA25
Voluntary and community services are not free but are essential to people with HIV. @bhiva.bsky.social #BHIVA25
Results from HIV Confident charter - still a lot of stigma and misunderstanding! On a positive note, 80% of HCPs would like more training! @bhiva.bsky.social #BHIVA25
Collaboration with Primary Care is key! How is clinic letter reviewed at GPs? Help them help you! @bhiva.bsky.social #BHIVA25
@bhiva.bsky.social Chair and Brightonian @profygilleece.bsky.social opens #BHIVA25 at the stunning #BrightonDome with a call for us all to defend and protect equality for all in increasingly difficult times 💪🏼👍🏼❤️ 🏳️🌈 🏳️⚧️ 🌍
